Home LiteratureArticle Details
PMID: 21881528 Published · ppublish English Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk.

Journal of hypertension ·Vol. 29 ·No. 10 ·2011-10-00 ·Pages 2004-13

Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlöf B, Poulter NR, ASCOT investigators

Abstract

Resistant hypertension is a well recognized clinical entity, which has been inadequately researched to date. A multivariable Cox model was developed to identify baseline predictors of developing resistant hypertension among 3666 previously untreated Anglo-Scandinavian Cardiac Outcome Trial (ASCOT) patients and construct a risk score to identify those at high risk. Secondary analyses included evaluations among all 19 257 randomized patients. One-third (1258) of previously untreated, and one-half (9333) of all randomized patients (incidence rates 75.2 and 129.7 per 1000 person-years, respectively) developed resistant hypertension during a median follow-up of 5.3 and 4.8 years, respectively. Increasing strata of baseline SBP (151-160, 161-170, 171-180, and >180 mmHg) were associated with increased risk of developing resistant hypertension [hazard ratio 1.24 (95% confidence interval, CI 0.81-1.88), 1.50 (1.03-2.20), 2.15 (1.47-3.16), and 4.43 (3.04-6.45), respectively]. Diabetes, left ventricular hypertrophy, male sex, and raised BMI, fasting glucose, and alcohol intake were other significant determinants of resistant hypertension. Randomization to amlodipine ± perindopril vs. atenolol ± thiazide [0.57 (0.50-0.60)], previous use of aspirin [0.78 (0.62-0.98)], and randomization to atorvastatin vs. placebo [0.87 (0.76-1.00)] significantly reduced the risk of resistant hypertension. Secondary analysis results were similar. The risk score developed allows accurate risk allocation (Harrell's C-statistic 0.71), with excellent calibration (Hosmer-Lemeshow χ statistics, P = 0.99). A 12-fold (8.4-17.4) increased risk among those in the highest vs. lowest risk deciles was apparent. Baseline SBP and choice of subsequent antihypertensive therapy were the two most important determinants of resistant hypertension in the ASCOT population. Individuals at high risk of developing resistant hypertension can be easily identified using an integer-based risk score.

MeSH Terms
Aged Algorithms Amlodipine/therapeutic use Antihypertensive Agents/therapeutic use Atenolol/therapeutic use Bendroflumethiazide/therapeutic use Diuretics/therapeutic use Drug Resistance Female Humans Hypertension/drug therapy,physiopathology Ireland Male Middle Aged Perindopril/therapeutic use Risk Factors Scandinavian and Nordic Countries United Kingdom
Chemicals
Antihypertensive Agents Diuretics Amlodipine Atenolol Bendroflumethiazide Perindopril
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Gupta Ajay K
International Centre for Circulatory Health, Imperial College London, London, UK. [email protected]
Nasothimiou Efthimia G
Chang Choon L
Sever Peter S
Dahlöf Bjorn
Poulter Neil R
ASCOT investigators
Article Info
Journal
Journal of hypertension
Abbr.
J Hypertens
ISSN
1473-5598
Published
2011-10-00
Pages
2004-13
Language
English
Region
England
NLM ID
8306882
Subset
IM
Grants
British Heart Foundation · United Kingdom
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]